Federal Register / Vol. 83, No. 247 / Thursday, December 27, 2018 / Notices 66751 

Dated: December 8, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–28078 Filed 12–26–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Myoderm 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before January 28, 2019. Such 

persons may also file a written request 

for a hearing on the application on or 

before January 28, 2019. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on 

November 2, 2018, Myoderm, 48 East 

Main Street, Norristown, Pennsylvania 

19401–4915 applied to be registered as 

an importer of the following basic 

classes of controlled substances: 

Controlled 

substance Drug code Schedule 

Amphetamine ........ 1100 II 

Lisdexamfetamine 1205 II 

Methylphenidate ... 1724 II 

Nabilone ................ 7379 II 

Oxycodone ............ 9143 II 

Hydromorphone .... 9150 II 

Hydrocodone ........ 9193 II 

Morphine ............... 9300 II 

Oxymorphone ....... 9652 II 

Fentanyl ................ 9801 II 

The company plans to import the 

listed controlled substances for clinical 

trials, research, and analytical purposes. 

Approval of permit applications will 

occur only when the registrant’s activity 

is consistent with what is authorized 

under to 21 U.S.C.952(a)(2). 

Authorization will not extend to the 

import of FDA approved or nonapproved finished dosage forms for 

commercial sale. 

Dated: December 8, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–28081 Filed 12–26–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Agilent Technologies 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before January 28, 2019. Such 

persons may also file a written request 

for a hearing on the application on or 

before January 28, 2019. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/OALJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DPW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on August 

13, 2018, Agilent Technologies, 250 

Smith Street, North Kingstown, Rhode 

Island 02852 applied to be registered as 

an importer of the following basic 

classes of controlled substances: 

Controlled substance Drug code Schedule 

Marihuana ................................................................................................................................................................ 7360 I 

Tetrahydrocannabinols ............................................................................................................................................ 7370 I 


khammond on DSK30JT082PROD with NOTICES
66752 Federal Register / Vol. 83, No. 247 / Thursday, December 27, 2018 / Notices 

1For purposes of this exemption, references to 

specific provisions of Title I of the Act, unless 

otherwise specified, should be read to refer as well 

to the corresponding provisions of the Code. 

This company plans to import the 

listed controlled substances in bulk 

form for testing and calibration only. 

The listed controlled substances are not 

for human or animal use. 

Dated: December 8, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–28080 Filed 12–26–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Registration 

ACTION: Notice of registration. 

SUMMARY: The registrant listed below 

has applied for and been granted 

registration by the Drug Enforcement 

Administration (DEA) as an importer of 

schedule I or schedule II controlled 

substances. 

SUPPLEMENTARY INFORMATION: 

The company listed below applied to 

be registered as an importer of various 

basic classes of controlled substances. 

Information on the previously published 

notice is listed in the table below. No 

comments or objections were submitted 

and no requests for hearing were 

submitted for this notice. 

Company: Fisher Clinical Services, 

Inc. 

FR Docket: 83 FR 53108. 

Published: October 19, 2018. 

The DEA has considered the factors in 

21 U.S.C. 823, 952(a) and 958(a) and 

determined that the registration of the 

listed registrant to import the applicable 

basic classes of schedule I or II 

controlled substances is consistent with 

the public interest and with United 

States obligations under international 

treaties, conventions, or protocols in 

effect on May 1, 1971. The DEA 

investigated the company’s maintenance 

of effective controls against diversion by 

inspecting and testing the company’s 

physical security systems, verifying the 

company’s compliance with state and 

local laws, and reviewing the company’s 

background and history. 

Therefore, pursuant to 21 U.S.C. 

952(a) and 958(a), and in accordance 

with 21 CFR 1301.34, the DEA has 

granted a registration as an importer for 

schedule I controlled substance to the 

above listed company. 

Dated: December 8, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–28076 Filed 12–26–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Employee Benefits Security 

Administration 

Exemptions from Certain Prohibited 

Transaction Restrictions 

AGENCY: Employee Benefits Security 

Administration, Labor. 

ACTION: Grants of Individual 

Exemptions. 

SUMMARY: This document contains 

exemptions issued by the Department of 

Labor (the Department) from certain of 

the prohibited transaction restrictions of 

the Employee Retirement Income 

Security Act of 1974 (ERISA or the Act) 

and/or the Internal Revenue Code of 

1986 (the Code). This notice includes 

the following: 2018–08, Liberty Media 

401(k) Savings Plan, D–11890; and 

2018–09, CLS Investments, LLC and 

Affiliates, D–11931. 

SUPPLEMENTARY INFORMATION: Notices 

were published in the Federal Register 

of the pendency before the Department 

of proposals to grant such exemptions. 

Each notice set forth a summary of the 

facts and representations made by the 

applicant for the exemption, and 

referred interested persons to the 

application for a complete statement of 

the facts and representations. Each 

application is available for public 

inspection at the Department in 

Washington, DC Each notice also 

invited interested persons to submit 

comments on the requested exemption 

to the Department. In addition, each 

notice stated that any interested person 

might submit a written request that a 

public hearing be held (where 

appropriate). Each applicant has 

represented that it has complied with 

the requirements of the notification to 

interested persons. No requests for a 

hearing were received by the 

Department. Public comments were 

received by the Department as described 

in the granted exemption. 

Each notice of proposed exemption 

was issued, and each exemption is being 

granted, solely by the Department, 

because, effective December 31, 1978, 

section 102 of Reorganization Plan No. 

4 of 1978, 5 U.S.C. App. 1 (1996), 

transferred the authority of the Secretary 

of the Treasury to issue exemptions of 

the type proposed to the Secretary of 

Labor. 

Statutory Findings 

In accordance with section 408(a) of 

the Act and/or section 4975(c)(2) of the 

Code and the procedures set forth in 29 

CFR part 2570, subpart B (76 FR 66637, 

66644, October 27, 2011) and based 

upon the entire record, the Department 

makes the following findings: 

(a) Each exemption is 

administratively feasible; 

(b) Each exemption is in the interests 

of the plan and its participants and 

beneficiaries; and 

(c) Each exemption is protective of the 

rights of the participants and 

beneficiaries of the plan. 

Liberty Media 401(k) Savings Plan (the 

Plan) Located in Englewood, CO 

[Prohibited Transaction Exemption 2018–08; 

Exemption Application No. D–11890] 

Written Comments 

In the Notice of Proposed Exemption 

published in the Federal Register on 

April 4, 2018 at 83 FR 14505 (the 

Notice), the Department invited all 

interested persons to submit written 

comments and requests for a hearing 

within thirty-seven (37) days of the date 

of the publication. All comments and 

requests for a hearing were due by May 

11, 2018. 

During the comment period, the 

Department received no comments and 

no requests for a public hearing. 

After full consideration and review of 

the entire record, the Department has 

determined to grant the exemption, as 

set forth above. The complete 

application file (D–11890) is available 

for public inspection in the Public 

Disclosure Room of the Employee 

Benefits Security Administration, Room 

N–1513, U.S. Department of Labor, 200 

Constitution Avenue NW, Washington 

DC 20210. 

For a more complete statement of the 

facts and representations supporting the 

Department’s decision to grant this 

exemption refer to the Notice published 

on April 4, 2018 at 83 FR 14505. 

Exemption 

Section I. Transactions 

Effective for the period beginning May 

24, 2016, and ending June 16, 2016, the 

restrictions of sections 406(a)(1)(E), 

406(a)(2), and 407(a)(1)(A) of the Act 1

shall not apply to: 

(a) The acquisition by the Plan of 

certain stock subscription rights (the 

Rights) to purchase shares of Series C 

Liberty Braves common stock (the Series 


khammond on DSK30JT082PROD with NOTICES